Showing 2681-2690 of 5646 results for "".
- RightEye Vision System Receives Breakthrough Device Designation from the FDA for Parkinson’s Disease Testhttps://modernod.com/news/righteye-vision-system-receives-breakthrough-device-designation-from-the-fda-for-parkinsons-disease-test/2477133/RightEye announced that the RightEye Vision System has received breakthrough device designation from the FDA for a Parkinson’s Disease Test. The designation is designed to streamline the market clearance
- NovaBay Pharmaceuticals Launches NovaWipes Eyelid Wipes on Amazon.comhttps://modernod.com/news/novabay-pharmaceuticals-launches-novawipes-eyelid-wipes-on-amazon-com/2477129/NovaBay Pharmaceuticals announced the launch of NovaWipes, a dry, soft, hypoallergenic and absorbable wipe for use in applying Avenova, on Amazon.com. Avenova Direct, NovaBay’s prescription-strength lid and lash spray, is also available on Amazon.com without a prescription. “Our soft and a
- Novartis to Acquire The Medicines Company for $9.7 Billionhttps://modernod.com/news/novartis-to-acquire-the-medicines-company-for-9-7-billion/2477118/Novartis confirmed Sunday that it has agreed to buy The Medicines Company for $85 per share in cash, or roughly $9.7 billion on a fully diluted equity basis, gaining the RNAi-based PCSK9 inhibitor inclisiran. Rumors initially surfaced last week that Novartis was looking to acquire the c
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Lightmed Introduces New Design of LIGHTLas TruScan Pro Photocoagulatorhttps://modernod.com/news/lightmed-introduces-new-design-of-lightlas-truscan-pro-photocoagulator/2477108/Lightmed announced the launch of LIGHTLas TruScan Pro V2.0, the advanced and flexible pattern-scanning laser that’s configurable with up to four different wavelengths. The upgraded LIGHTLas TruScan Pro V2.0 features a slit lamp and integrated delivery system design, and a new ergonomic single col
- Report: Novartis Weighing Takeover Offer for The Medicines Companyhttps://modernod.com/news/report-novartis-weighing-takeover-offer-for-the-medicines-company/2477107/Novartis is considering making an offer to acquire The Medicines Company and is currently conducting due diligence on the drugmaker, Bloomberg reported Tuesday, citing people close to the matter. The sources suggested that The Medicines Company, which has a market value of about $4.7 bi
- NovaBay Pharmaceuticals Launches NovaSight Daily Vitamin for Ocular Health on Amazon.comhttps://modernod.com/news/novabay-pharmaceuticals-launches-novasight-daily-vitamin-for-ocular-health-on-amazon-com/2477099/NovaBay Pharmaceuticals announced the launch of NovaSight, a proprietary daily vitamin and mineral supplement specially formulated to support ocular health, on Amazon.com. NovaSight is a companion product to Avenova Direct, NovaBay’s prescription-strength lid and lash spray available on Amazon.co
- Biogen Gains Commercialization Rights to Anti-VEGF Biosimilar Candidates After Deal with Samsung Bioepishttps://modernod.com/news/samsung-bioepis-enters-into-commercialization-agreement-for-next-generation-biosimilar-candidates/2477072/Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States, Canada, Europe, Japan, and Australia. SB11, a biosimilar candidate referencing Lucent
- Trump to Nominate Stephen Hahn, Cancer Researcher, to Head FDAhttps://modernod.com/news/trump-to-nominate-stephen-hahn-cancer-researcher-to-head-fda/2477068/President Trump said Friday that he intended to nominate Stephen M. Hahn, MD, a top executive at The University of Texas M.D. Anderson Cancer Center, to be the next commissioner of the Food and Drug Administration, according to a
- EyePoint Pharmaceuticals Announces Addition of Dexycu and Yutiq to Department of Veteran Affairs Federal Supply Schedulehttps://modernod.com/news/eyepoint-pharmaceuticals-announces-addition-of-dexycu-and-yutiq-to-department-of-veteran-affairs-federal-supply-schedule/2477065/EyePoint Pharmaceuticals announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs (VA) for Dexycu and Yutiq to be included on the Federal Supply Schedule (FSS), providing U.S. veterans and other federal government agencies with access to both products. The VA